Malignant melanoma continues to be a challenge both in terms of understanding the biologic mechanisms behind its behaviour and applying that information toward developing new therapeutic interventions. Although malignant melanoma represents only 5% of all skin cancers, it is responsible for 80% of all skin cancer-related deaths ([@bib27]; [@bib33]). In 2012 alone, an estimated 232 000 new cases of invasive melanoma and 55 000 deaths occurred globally ([@bib26]). The high death rate in melanoma is attributable to the high metastatic potential of melanoma and resistance to apoptosis. Five-year survival rate with metastatic melanoma is only 5--16% compared with a 90% survival rate in patients with early-stage, localised melanoma ([@bib35]; [@bib16]; [@bib27]; [@bib33]), highlighting the need to understand tumour progression in melanoma to enable development of novel effective therapies.

Although melanoma is a disease that primarily arises in the skin, it is a derivative of the neural crest. During embryogenesis, an epithelial-to-mesenchymal transition occurs to form these cells. Once formed, neural crest cells migrate to various body locations and differentiate into cells of the central and peripheral nervous system, cells of the adrenal medulla, various craniofacial connective tissues and melanocytes ([@bib7]; [@bib10]). The histopathologic progression in melanocytic transformation is described as follows ([@bib4]): (1) normal skin has an even distribution of dendritic melanocytes throughout the basal layer; (2) benign proliferation of melanocytes -- in a nevus, nevoid melanocytes are organised into uniform nests of cells; (3) melanocyte dysplasia -- a dysplastic nevus has irregular and bridging nests of cells consisting of large atypical melanocytes; (4) *in situ* melanoma, radial growth phase (RGP) -- single dysplastic cells are present in the epidermis (Pagetoid spread); (5) malignant melanoma, the vertical growth phase (VGP). Clark level of invasion and Breslow thickness have a strong predictive value in the prognosis of patients with non-metastatic melanomas. Most VGP, tumorigenic, melanomas evolve within an RGP plaque. The VGP, unlike the RGP, is associated with a chance for distant metastasis. Nodular melanomas (NMs) evolve directly from apparently normal skin to VGP. Approximately 45% of new melanoma cases are entirely in the RGP, 10% are in the VGP alone and the remaining 45% have a VGP tumour nodule surrounded by an RGP plaque ([@bib8]). The RGP subtypes include: superficial spreading melanoma (SSM), lentigo maligna melanoma, acral lentiginous melanoma (LM) and mucosal LM. Superficial spreading melanomas represent 70%, NMs represent 10--30% and LMs ∼5% of all melanomas ([@bib4]). An association between genetic alterations and morphologic findings supports the existence of biologically distinct melanoma subtypes and stages of melanoma progression ([@bib17]; [@bib22]).

Targeting translation has been suggested as a novel strategy for therapy of malignancies originating in the epithelium ([@bib12], [@bib15], [@bib13], [@bib14]; [@bib34]). Eukaryotic translation initiation factor 4E regulates the translation of multiple malignancy-associated mRNAs. Eukaryotic translation initiation factor 4E is overexpressed in many human and experimental tumours. Reducing eIF4E expression reduces tumour growth and metastases. Eukaryotic translation initiation factor 4E is released from the translation inhibitor 4E-BP1 upon hyperphosphorylation of 4EB-P1 by mTOR ([@bib11]). Phosphorylation of 4E-BP1 is associated with poor survival in melanoma patients ([@bib28]), suggesting that increased translation initiation may be a common event in melanoma and is associated with poor prognosis. In BRAF^v600E^ melanoma cell lines, the chemotherapeutic agent vemurafenib inhibits 4E-BP1 phosphorylation. In cells with an acquired resistance to vemurafenib, there is an increased dependence on eIF4E for cell survival ([@bib43]).

Although phosphorylation of 4E-BP1 releases eIF4E, eIF4E is further activated by phosphorylation downstream of the Mnk 1 and 2 kinases ([@bib39]). The role of eIF4E phosphorylation in transformation and histopathologic progression of melanocytes to melanomas has not been reported previously. However, inhibition of eIF4E phosphorylation by the Mnk inhibitor cercosporamide reduces the outgrowth of B16 lung metastases in mice *in vivo* and at concentrations that effectively inhibit eIF4E phosphorylation, blocks cell proliferation, anchorage-independent growth and elicits apoptosis in B16 melanoma cells *in vitro* ([@bib25]). Western blot data indicate that phospho-eIF4E as well as eIF4E are found in seven melanoma cell lines including N-RAS and BRAF/PTEN mutant melanoma cell lines ([@bib28]). More than 50% of human melanomas have BRAF mutations and another 20% show N-RAS mutations ([@bib2]). Both would be expected to elevate Mnk activity and by extension eIF4E phosphorylation.

These data suggested the hypothesis that eIF4E phosphorylation is important in the development of human malignant melanoma, in melanoma progression to metastasis and signals increased risk of death from melanoma. If so, inhibition of eIF4E phosphorylation may be a novel target for melanoma therapy. We addressed this hypothesis by semiquantitative immunohistochemical (IHC) evaluation of eIF4E and phospho-eIF4E expression in archived surgical specimens of multiple subtypes of melanocytic lesions in patients in relation to their clinical outcome and death. We determined that phospho-eIF4E was associated with malignancy and was increased in subtypes of melanoma with increased metastatic potential. Elevated phospho-eIF4E was prognostic of reduced patient survival and associated with increased risk of death from melanoma. Taken together, these data validate in surgical specimens of human malignant melanomas the numerous experimental studies of the role of translation in cancer development and metastatic progression ([@bib29]). Our data give evidence that elevated phosphorylation of eIF4E serine 209 in surgical specimens is associated with malignancy, metastases and reduced survival in malignant melanoma and suggest that inhibition of eIF4E phosphorylation may be a novel approach to therapy of human malignant melanoma.

Materials and methods
=====================

Tissues studied
---------------

Archived, formalin-fixed, paraffin-embedded (FFPE) tissues were donated to Wood Hudson Cancer Research Laboratory by St Elizabeth Healthcare in Northern Kentucky and are preserved in the environmentally controlled Wood Hudson Biospecimen Repository. The study had the approval of the St Elizabeth Healthcare Institutional Review Board and Wood Hudson Cancer Research Laboratory has an HIPAA waiver from St Elizabeth Healthcare.

A total of 149 archived FFPE surgical specimens from 114 patients obtained at surgeries performed between 1981 and 2006 were stained and evaluated. Melanocytic lesions were classified according to the subtype in H&E-stained histologic sections by a Board Certified pathologist (LED). Included in the study were 23 patients with 35 dermal, compound or junctional nevi, 34 patients with SSM, 21 patients with 22 LMs, 16 patients with NM and 20 patients with 42 dermal, lymph node or visceral metastases (metastatic melanoma (MM)) ([Table 1](#tbl1){ref-type="table"}).

Clinical follow-up was obtained from Tumour Registries with the assistance of Tumour Registrars at St Elizabeth Healthcare. Survival information was available for up to 30 years.

Immunohistochemistry
--------------------

Air-dried 5-*μ*m paraffin sections were dewaxed in Clearite, and rehydrated through a graded series of alcohols to distilled water. They were placed in tris-buffered saline (TBS) containing 0.05% Tween. Following rehydration, antigen retrieval was with 0.1 [M]{.smallcaps} citrate buffer, pH 6.0, heated to 95 °C in a water bath for 20 min. Sections were allowed to cool for 20 min, and then rinsed in deionised water and placed in TBS-Tween. Adjacent sections were stained immunohistochemically for the expression of eIF4E with a mouse monoclonal antibody (BD Biosciences, New York, NY, USA; cat. no.: 610270, 1.67 mg ml^−1^) or mouse IgG2B control (Dako, Carpinteria, CA, USA; cat. no.: X0931, 1.67 mg ml^−1^) and phosphorylated eIF4E with a rabbit monoclonal antibody (Novus Biologicals, Littleton, CO, USA; cat. no. NB 100-79938, 1.42 mg ml^−1^) or rabbit IgG control (Dako; cat. no.: X0903, 1.42 mg ml^−1^) for 60 min using a Dako autostainer and the Dako LSAB2 staining system (Dako) with diaminobenzidine as chromagen. Antibody specificity was established as reported previously ([@bib15], [@bib14]; [@bib9]; [@bib18]; [@bib25]). Immunohistochemically stained sections were counterstained with methyl green, dehydrated in butanol and Clearite and coverslipped with Permount (Fisher Healthcare, Hanover Park, IL, USA). A slide from a single case was included in every IHC run as a staining control along with a buffer control.

Immunohistochemically stained sections were evaluated semiquantitatively by two observers (LED and JHC or NRS) using a Nikon Coolscope (Nikon Instruments, Inc., New York, NY, USA). Histoscores (HS) were calculated from the intensity of the stain and the area of the epithelium stained (HS=intensity × area). Intensity was negative (0), trace (0.5), light (1+), moderate (2+) or intense (3+). Area was negative (0), 1--25% stained (0.1), 26--50% stained (0.4), 51--75% stained (0.6) or 76--100% stained (0.9). Cytoplasmic stain and nuclear stain were recorded separately. Observers were blinded to patient outcome.

Study design
------------

This was a retrospective study in which melanoma cases were selected from tumour registries without the knowledge of melanoma subtype or clinical outcome. Clinical information obtained as part of the study included patient age and gender, date of diagnosis, stage of disease, depth of invasion (Clark level), date of recurrence, site of metastases, date of death (or date known to be alive) and if death was due to melanoma. Variables analysed were cytoplasmic and nuclear HS for eIF4E and phospho-eIF4E, subtype of melanocytic lesion, age, depth of invasion and survival.

Statistical analyses
--------------------

The data consist of 149 specimens, from 114 patients, with follow-up data on 88 patients. Means and standard errors were computed for age, and for all markers by tissue type. Data analysis included *t*-tests, nonparametric Wilcoxon\'s tests and repeated-measures ANOVA (to account for multiple observations per patients). For those patients with follow-up information, Kaplan--Meier survival analyses were performed with log-rank statistics, and Cox proportional hazard regression were performed using IHC HS data for cytoplasmic or nuclear eIF4E staining and cytoplasmic or nuclear phospho-eIF4E. The 75th percentile of staining, expressed as HS for each marker in the 88 patients used in the survival analysis, was chosen *a priori* as the cut-point for the Kaplan--Meier analyses. The proportional hazards Cox model was used to determine the hazard ratios (HRs) adjusted for age and lesion histopathologic subtype. The Cox model was also used to analyse the continuous raw scores for all markers. All analyses were carried out using SAS 9.3 (SAS Institute, Inc., Cary, NC, USA).

Results
=======

Histopathologic subtypes of cutaneous melanoma and patient characteristics determine survival
---------------------------------------------------------------------------------------------

Human melanoma is a heterogeneous disease. We studied the three major histopathologic subtypes of primary cutaneous melanoma ([Figure 1](#fig1){ref-type="fig"}) as well as metastatic melanoma to characterise differences in patient survival based on melanoma subtype and patient age and gender.

### Superficial spreading melanoma

Superficial spreading melanomas is the most frequent histopathologic type of melanoma encountered ([Figure 1A](#fig1){ref-type="fig"}). It begins with an RGP in the epidermis, characterised by the presence of individual melanoma cells and clusters of melanoma cells in both the deep and in the more superficial layers of the epidermis. This RGP may be followed by a VGP during which the melanoma infiltrates into all layers of the dermis and into the subcutaneous tissue.

### The LMs: acral LM, mucosal LM and lentigo maligna melanoma

These three melanomas have one thing in common histopathologically; the RGP is almost entirely limited to the basal layer of the epidermis ([Figure 1B](#fig1){ref-type="fig"}). This RGP may be followed by a VGP extending into the dermis and subcutaneous tissue. These three LMs differ in the sites in which they arise. Acral LMs arise on the distal extremities. Mucosal LMs are found at sites not ordinarily exposed to sunlight. Lentigo maligna melanomas arise in the skin more commonly associated with exposure to sunlight.

### Nodular melanoma

Nodular melanomas are the second most frequent histopathologic type of melanoma and are associated with the greatest mortality ([Figure 1C](#fig1){ref-type="fig"}). The tumours appear to arise in the dermis, unassociated with the overlying epidermis. Even when the melanoma is seen to be immediately below the epidermis, and even to touch it, the two appear to remain separate. The NM has only a VGP. It appears to be unassociated with an RGP and is associated with a chance for distant metastasis.

We found that patient age and melanoma subtype determined survival. Average age of patients with benign nevi (37±3) was significantly younger compared with that of patients with malignant melanoma (*P*=0.0001). Average age of patients with SSM (54±3), NM (58±5) and metastases (53±2) was younger compared with that of patients with LM (70±3) (*P*=0.0004). Male and female patients were of similar ages for each lesion type ([Table 1](#tbl1){ref-type="table"}).

Although statistical analyses found that age was a confounding factor for survival, younger patients had a poorer outcome. The age difference in survival was a consequence of the difference in lethality between the malignant melanoma subtypes ([Figure 1D](#fig1){ref-type="fig"}). Survival in patients with RGP melanoma subtypes (SSM and LM) differed significantly from patients with NMs or MMs (*P*\<0.0001; [Figure 1E](#fig1){ref-type="fig"}). Whereas 75% of patients with NM and 70% of patients with MM died, only 21% of patients with SSM and 33% of patients with LM died from melanoma ([Table 1](#tbl1){ref-type="table"}). Consistent with this observation, the depth of invasion as assessed by Clark level was related to survival as 13% of patients with Clark level I and II died compared with 36% of patients with Clark level III, IV or V tumours.

Increased eIF4E and phospho-eIF4E expressions are associated with malignancy
----------------------------------------------------------------------------

Immunohistochemical detection of eIF4E and phospho-eIF4E expression was assessed in the cytoplasm and nucleus of 149 specimens of melanocytic lesions from 114 patients ([Table 2A](#tbl2A){ref-type="table"}, [2B](#tbl2B){ref-type="table"}, [2C](#tbl2C){ref-type="table"}). Uniformly high expression of eIF4E and phospho-eIF4E was seen in nearly all individual malignant melanocytes, whereas light to moderate staining was scattered in occasional cells within benign nevi ([Figure 2](#fig2){ref-type="fig"}). All but two melanocytic lesions (99%) had eIF4E cytoplasmic stain and all but five lesions (97%) stained positively for nuclear eIF4E. Only one melanocytic lesion did not have cytoplasmic phospho-eIF4E expression. However, nuclear phospho-eIF4E was absent in 24% of the specimens (35 lesions), including 26 of 36 nevi (72%) and 5 of 45 RGP lesions (11%), suggesting an association between malignancy and expression of nuclear phosph-eIF4E. Indeed, both cytoplasmic and nuclear expression of eIF4E and phospho-eIF4E were significantly increased in all malignant melanomas compared with benign nevi (*P*\<0.0001 for all markers by both ANOVA and nonparametric tests) ([Table 2A](#tbl2A){ref-type="table"} and [2B](#tbl2B){ref-type="table"} and [Figure 2A and B](#fig2){ref-type="fig"}).

Significant differences were found in cytoplasmic expression of eIF4E and phospho-eIF4E between dermal, compound and junctional nevi (*P*=0.0324 and 0.0012, respectively, by ANOVA) with junctional nevi having marginally or significantly higher expression (*P*=0.0645 and 0.0011, respectively).

Nuclear phospho-eIF4E was related to depth of invasion of superficial spreading melanomas assessed by Clark level, nuclear HS=0.19±0.05 for 21 Clark level I and II lesions *vs* 0.54±0.07 for Clark level ⩾III (*P*=0.0010 by ANOVA, *P*=0.0006 by nonparametric tests). Correlation analysis showed that Clark level was significantly associated with nuclear phospho-eIF4E (*P*=0.001) but not with any other variable ([Table 2C](#tbl2C){ref-type="table"}). Nuclear expression of phospho-eIF4E was also highly associated with patient\'s age (*P*=0.002) and lesion subtype (*P*\<0.0001). Highly significant correlations between nuclear and cytoplasmic phospho-eIF4E and nuclear and cytoplasmic eIF4E with patient\'s age and lesion subtype were also found ([Table 2C](#tbl2C){ref-type="table"}). Age and lesion subtype were highly correlated (*P*=0.0002).

Increased eIF4E and phospho-eIF4E expression are associated with metastatic potential
-------------------------------------------------------------------------------------

Superficial spreading melanoma and LM in the RGP do not have metastatic potential, whereas SSM and LM in the VGP and NM have metastatic potential. We asked if eIF4E and phospho-eIF4E expression differed in the RGP compared with the VGP. In 28 RGP *vs* 19 VGP melanomas significant increases occurred in the VGP in the expression of cytoplasmic eIF4E (HS 2.271 *vs* 1.772, *P*=0.0207), cytoplasmic phospho-eIF4E (HS 2.021 *vs* 1.508, *P*=0.0080) and nuclear phospho-eIF4E (HS 0.693 *vs* 0.329, *P*=0.0029).

Melanomas in an RGP had significantly less cytoplasmic eIF4E (HS 1.772 *vs* 2.240, *P*=0.0381) and significantly less nuclear phospho-eIF4E (HS 0.329 *vs* 0.646, *P*=0.0249) compared with NM. Significant differences in eIF4E and phospho-eIF4E expression were not found in melanomas in a VGP compared with NMs, both of which have metastatic potential.

Dermal, lymph node and distant metastases were evaluated for differences in eIF4E and phospho-eIF4E expression ([Table 2A](#tbl2A){ref-type="table"}). All metastases irrespective of metastatic site had similar eIF4E and phospho-eIF4E expression. Metastatic lesions had increased eIF4E and phospho-eIF4E expression relative to both benign nevi (*P*\<0.0001, all markers) and melanomas in an RGP (*P*=0.0073 eIF4E cytoplasmic, *P*=0.0092 eIF4E nuclear, *P*=0.0401 phospho-eIF4E cytoplasmic and *P*=0.0138 phospho-eIF4E nuclear). Melanoma metastases did not differ in eIF4E and phospho-eIF4E expression from NMs (*P*\>0.9, all markers).

Follow-up of patients with primary tumours, including eight NMs, four LMs, and three SSMs, who subsequently developed metastases, or who had synchronous metastases indicated that those primary tumours with high nuclear phospho-eIF4E frequently metastasised (*P*=0.0059). The means and medians for eIF4E and phospho-eIF4E in the primary tumour or regional metastases in patients who later developed either regional or distant metastases were greater than the means and medians of all patients with melanocytic lesions. Expression of eIF4E or phospho-eIF4E in tumours from patients with melanocytic lesions who developed later metastases was higher by any measure including raw score, rank or percentile.

Increased eIF4E and phospho-eIF4E expression are associated with reduced survival
---------------------------------------------------------------------------------

The 75th percentiles of staining for eIF4E and phospho-eIF4E expression were chosen *a priori* as cut-points for all Kaplan--Meier analyses to reduce the degrees of freedom associated with survival analyses. A cut-point of 2.7 for cytoplasmic HS for eIF4E was associated with death from melanoma (*P*=0.0271). An association between nuclear eIF4E expression and melanoma death was not found using a cut-point of 0.9 (*P*=0.4994). Using the cytoplasmic HS of 2.25 for phospho-eIF4E as a cut-point showed a highly significant association with death (*P*=0.0011). Nuclear phospho-eIF4E was highly associated with death from melanoma using a cut-point of 0.65 for nuclear HS (*P*=0.0042).

Using the 75th percentiles of eIF4E expression as cut-points for Kaplan--Meier analysis demonstrated highly significant association for high cytoplasmic eIF4E with poor survival in all patients, and a trend in patients with NM and MM ([Figure 3A and B](#fig3){ref-type="fig"}, *P*=0.0191, 0.0573). In contrast, a significant association of high cytoplasmic eIF4E HS with death from melanoma was not found in patients with SSM and LM (*P*=0.2250). Significant associations between nuclear eIF4E HS ⩾0.9 and survival were not found ([Figure 3C and D](#fig3){ref-type="fig"}).

Kaplan--Meier analyses demonstrated highly significant associations between high cytoplasmic HS for cytoplasmic phospho-eIF4E and reduced survival in all patients (*P*=0.0003) and in patients with NM or MM (*P*=0.0141) ([Figure 3E and F](#fig3){ref-type="fig"}) but not with patients with SSM and LM (*P*=0.6013). High nuclear phospho-eIF4E was highly associated with poor survival in all patients (*P*=0.0009) and in patients with NM and MM (*P*=0.0232) ([Figure 3G and H](#fig3){ref-type="fig"}). In SSM and LM, high nuclear phospho-eIF4E was not associated with poor survival (*P*=0.2252).

The Cox proportional HR analyses for phospho-eIF4E expression demonstrated significantly increased HRs in all patients and in patients with NM and MM but not in patients with SSM and LM ([Table 3](#tbl3){ref-type="table"}). The *P*-values were adjusted for age in patients with NM and MM and with SSM and LM. The *P*-values were adjusted for both age and melanoma subtype in the Cox proportional analysis for all patients. The *P*-value (0.7059) for the HR for phospho-eIF4E was not significant, but a piecewise model was significant with low risk up to about an HS of 1.8 then increasing risk above 1.8. The HR for phospho-eIF4E cytoplasmic and nuclear expression were significantly better for SSM and LM (1.13 and 2.00, cytoplasmic and nuclear HRs, respectively) compared with NM and MM (3.66 and 2.93, cytoplasmic and nuclear HR, respectively) (*P*-value\<0.0001). Superficial spreading melanoma had a significantly better HR compared with all other melanocytic lesions (*P*-value=0.0007). An increased HR was found for cytoplasmic eIF4E for all patients adjusted for age (HR 2.01, *P*-value=0.0342) but not for NM and MM (HR 2.22, *P*-value=0.0616) or SSM and LM alone (HR 1.45, *P*-value=0.4936) ([Table 3](#tbl3){ref-type="table"}).

We conclude from these data that increased eIF4E and phospho-eIF4E expression are associated with the development of malignant melanoma, increased risk of metastasis, reduced survival and increased risk of death from melanoma. Even adjusting for confounding factors such as age and subtype of melanoma, the HR for death from melanoma is significantly increased in all patients by increased eIF4E and phospho-eIF4E expression in their tumour.

Discussion
==========

Numerous reports document the importance of eIF4E in cell transformation, growth of tumours and progression to metastases in epithelial cells and fibroblasts ([@bib29]). Because of the limited amount of tissue available, few studies have validated these results in human melanomas. While arising in the skin, melanocytes are derivatives of the neural crest. We believe this is the first report of a detailed analysis of the role of eIF4E and its phosphorylation during the development of human malignant melanoma and progression to metastasis in histopathologic subtypes of melanocytic lesions. This study suggests that eIF4E and phospho-eIF4E are predictive of the malignant potential of melanocytes and are associated with poor clinical outcome including reduced survival and increased risk of death.

eIF4E overexpression in experimental cell models results in only small increases in overall protein synthesis rates while enabling a substantial, disproportionate and selective increase in translation of a subset of mRNAs encoding key proteins involved in critical steps of cancer initiation and progression including cMYC, cyclin D1, ODC, VEGF and others. Very modest changes in expression of eIF4E are required to affect malignancy. Only two- to three-fold increases in eIF4E are sufficient to drive cellular transformation in experimental models ([@bib13]; [@bib19]; [@bib29]). Here we found a doubling of cytoplasmic eIF4E and a tripling of nuclear eIF4E in melanomas compared with benign nevi ([Table 2A](#tbl2A){ref-type="table"}). Moreover, both cytoplasmic and nuclear eIF4E were significantly increased in NM and MM, that is, the more lethal lesions ([Figure 1E](#fig1){ref-type="fig"}) compared with SSM and LM (*P*=0.0087 and 0.0403, respectively).

The phosphorylation of eIF4E at serine 209 is shown to be essential to the oncogenic function of eIF4E ([@bib36]; [@bib42]; [@bib9]). Oncogenic RAS markedly increases the rate of eIF4E phosphorylation, and RAS pathway signalling through ERK stimulates the Mnk kinases to phosphorylate eIF4E at serine 209 ([@bib31]; [@bib23]; [@bib39]). In experimental models, inhibition of Mnk activity delays tumour development and outgrowth of metastases ([@bib38]; [@bib25]). Inhibition of Mnk represses the invasive/mesenchymal phenotype in experimental models of EMT and metastasis ([@bib32]).

We found a four-fold increase in cytoplasmic phospho-eIF4E and a nine-fold increase in nuclear phospho-eIF4E in melanomas compared with benign nevi ([Table 2A](#tbl2A){ref-type="table"}). Thus, phosphorylation of eIF4E was critical to malignant conversion of melanocytes and was significantly increased in the cytoplasm and nucleus of melanocytes in NM and MM relative to SSM and LM (*P*=0.0143 and 0.0044, respectively).

The association of high levels of nuclear phospho-eIF4E with primary melanomas that metastasised is consistent with the experimental data demonstrating that eIF4E phosphorylation stimulates the translation of prosurvival and proinvasion mRNAs, thereby regulating transforming growth factor-β-induced EMT ([@bib42]; [@bib9]; [@bib32]). Nuclear localisation of phospho-eIF4E in surgical specimens of NMs and MMs is a novel finding and has no clear explanation, but is prognostic of metastases when found in primary melanomas of all subtypes including SSM, LM and NM. Nuclear localisation of phospho-eIF4E may have utility as a marker for metastatic potential in malignant melanoma as well as be an adverse prognostic factor for survival.

Our data suggest that targeting eIF4E or eIF4E phosphorylation may be an attractive therapeutic strategy in malignant melanoma. Targeting eIF4E function with an ASO against eIF4E (LY2275796) was tested in cell lines and in xenograft models with promising activity ([@bib15]). Translation of known eIF4E-specific progrowth and prosurival gene products was reduced by LY2275796, whereas global protein synthesis was only modestly affected. A phase 1 trial showed that LY2275796 could be safely administered to patients and was effective at decreasing eIF4E mRNA and protein levels in tumour cells ([@bib18]). Since elevated eIF4E is associated with resistance to doxorubicin, rapamycin, PI3K/mTOR kinase inhibitors and anti-BRAF or anti-MEK therapies ([@bib40], [@bib41]; [@bib20]; [@bib3]; [@bib5]), LY2275796 may act synergistically to increase the efficacy of these treatments or to overcome resistance. In mesothelioma cells, eIF4E knockdown with LY2275796 results in decreased expression of antiapoptotic and progrowth proteins and enhances chemosensitivity to cytarabine ([@bib21]).

In our study, increased phospho-eIF4E was strongly associated with a marked reduction in survival and an increase in the HR for death from melanoma. Coupled to the wealth of data implicating activation of the ras-raf-ERK-MEK-MNK pathway signalling in metastatic melanoma ([@bib2]), inhibiting eIF4E phosphorylation may be another promising therapeutic strategy for malignant melanoma. Indeed, increased 4E phosphorylation has been specifically associated with the expression of the oncogene BRAF^V600E^ in melanocytes ([@bib6]). Blocking eIF4E phosphorylation prevents the oncogenic function of eIF4E in multiple experimental models ([@bib42]; [@bib9]; [@bib25]), suggesting that pharmacologic inhibition of the Mnk kinases may be a promising therapeutic strategy. The Mnk inhibitors CGP57380 and cercosporamide block eIF4E phosphorylation in cultured cells limiting cellular proliferation in large part by inducing apoptosis ([@bib37]; [@bib24]; [@bib25]). Inducing apoptosis may be an 'Achilles\' heel\' for melanomas, which are known to be resistant to apoptosis ([@bib35]). Oral administration of cercosporamide suppressed eIF4E phosphorylation in normal mouse tissues and xenograft tumour tissues and profoundly suppressed the outgrowth of B16 melanoma metastases ([@bib25]). Cercosporamide treatment at doses that inhibited eIF4E phosphorylation decreased the growth rate of acute myeloid leukaemia (AML) xenografted tumours and suppressed colonisation of freshly explanted AML patient samples ([@bib1]). Moreover, cercosporamide enhanced the antileukaemic effects of cytarabine *in vitro* and *in vivo*, suggesting the potential efficacy of combining Mnk inhibitors with other drugs.

Whichever approach is taken, inhibition of either eIF4E or eIF4E phosphorylation, the near uniform expression of these proteins in malignant melanocytes as seen in [Figure 2](#fig2){ref-type="fig"} suggests that either approach may overcome tumour heterogeneity that can result in the selection of resistant malignant melanocytes, malignant progression and therapeutic failure ([@bib30]).
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![Melanocytic lesion histopathologic subtypes and survival. (**A**) Superficial spreading melanoma, × 400, haematoxylin and eosin (H&E) stain. (**B**) Lentiginous melanoma, × 400, H&E stain. (**C**) Nodular melanoma, × 400, H&E stain. (**D**) Patient survival is related to melanocytic lesion histopathologic subtype. Survival is better in SSM\>LM\> MM\>NM. (**E**) Patients with SSM and LM have better survival than patients with NM and MM.](bjc2015450f1){#fig1}

![(**A**) Eukaryotic translation initiation factor 4E cytoplasmic and nuclear stain in melanocytic lesions. (a) Eukaryotic translation initiation factor 4E cytoplasmic HS (area stained × stain intensity) are increased in malignant melanomas compared with benign nevi (*P*-value \<0.0001). (b) Eukaryotic translation initiation factor 4E stain in benign nevus. Note scattered lightly stained cells, × 400. (c) Eukaryotic translation initiation factor 4E stain in SSM, RGP, × 400. (d) Eukaryotic translation initiation factor 4E stain in SSM, VGP. Note intense and uniform stain in the lesion, × 400. (e) Eukaryotic translation initiation factor 4E nuclear HS are increased in malignant melanomas compared with benign nevi (*P*-value \<0.0001). (f) Uniform cytoplasmic stain in an NM for eIF4E, × 400. (g) Intense uniform cytoplasmic staining for eIF4E in MM, × 400. (h) Metastatic melanoma, mouse IgG2B-negative control, × 400. (**B**) Phosphorylated eIF4E cytoplasmic and nuclear stain in melanocytic lesions. (a) Phosphorylated eIF4E (phospho-eIF4E) cytoplasmic HS are increased in malignant melanomas compared with benign nevi (*P*-value \<0.0001). (b) Phospho-eIF4E stain in benign nevus. Nevus is devoid of significant stain, × 400. (c) Phospho-eIF4E stain in SSM, RGP. Note less stain in SSM compared with the adjacent skin, × 400. (d) Phospho-eIF4E stain in SSM, VGP, × 400. (e) Phospho-eIF4E nuclear HS are increased in malignant melanomas compared with benign nevi (*P*-value \<0.0001). (f) Uniform intense cytoplasmic and nuclear stain in an NM for phospho-eIF4E, × 400. (g) Uniform intense cytoplasmic and nuclear staining for phospho-eIF4E in MM, × 400. (h) Metastatic melanoma, rabbit IgG negative control, × 400.](bjc2015450f2){#fig2}

![Kaplan--Meier curves of patient survival according to cytoplasmic eukaryotic translation initiation factor 4E and cytoplasmic and nuclear phospho-eIF4E expression in melanocytic histopathologic subtypes. Significant differences in survival were not found with nuclear eIF4E. Cutoff values chosen *a priori* were the 75th percentile of each marker. (**A**) Patients with any form of melanoma who have at or above the 75th percentile of cytoplasmic eIF4E expression have reduced survival. (**B**) Patients with NM or MM who have at or above the 75th percentile of cytoplasmic eIF4E expression have a reduced survival trend. (**C**) Patients with any form of melanoma who have at or above the 75th percentile of nuclear eIF4E expression do not have reduced survival. (**D**) Patients with NM or MM who have at or above the 75th percentile of nuclear eIF4E expression do not have reduced survival. (**E**) Patients with any form of melanoma who have at or above the 75th percentile of cytoplasmic phospho-eIF4E expression have reduced survival. (**F**) Patients with NM or MM who have at or above the 75th percentile of cytoplasmic phospho-eIF4E expression have reduced survival. (**G**) Patients with any form of melanoma who have at or above the 75th percentile of nuclear phospho-eIF4E expression have reduced survival. (**H**) Patients with NM or MM who have at or above the 75th percentile of nuclear phospho-eIF4E expression have reduced survival.](bjc2015450f3){#fig3}

###### Tissues studied: Melanocytic lesion histopathologic subtype, patient gender, age and death from melanoma

  **Lesion subtype**              **No. of lesions**   **No. of males**   **No. of females**   **Av. age males**   **Av. age females**   **No. died of melanoma**   **No. in survival study**
  ------------------------------- -------------------- ------------------ -------------------- ------------------- --------------------- -------------------------- ---------------------------
  Nevi                            35                   11                 12                   37.5±5.7            33.5±4.3              0                          0
   Dermal nevi                    21                   8                  5                    40.4±6.5            36.8±5.1              0                          0
   Compound nevi                  11                   2                  6                    19.0±10.0           32.7±7.7              0                          0
   Junctional nevi                3                    2                  1                    40.0±12.0           22.0                  0                          0
  SSM                             34                   17                 17                   54.8±3.1            53.1±4.4              7                          34
  LM                              22                   10                 11                   71.2±4.2            68.4±5.2              7                          20
   Acral lentiginous melanoma     6                    3                  3                    77.0±4.2            71.7±1.5              2                          6
   Lentigo maligna melanoma       13                   6                  6                    67.8±6.5            66.7±8.0              3                          11
   Mucosal lentiginous melanoma   3                    1                  2                    74.0                68.5±22.5             2                          3
  NM                              16                   8                  8                    53.3±8.8            62.6±4.8              12                         14
  MM                              42                   13                 7                    55.1±2.9            59.1±4.9              14                         20
   Dermal metastases              7                    5                  0                    56.0±5.7                                  1                          2
   Lymph node metastases          28                   15                 5                    55.7±3.7            59.0±6.3              11                         14
   Distant metastases             7                    5                  2                    57.4±7.0            59.5±10.5             1                          3
   Clark level I and II           23                   8                  15                   51.9±4.6            58.3±5.3              3                          23
   Clark level ⩾III               44                   25                 17                   60.2±3.6            587±3.6               15                         40

Abbreviations: LM=lentiginous melanomas; MM=metastatic melanoma; NM=nodular melanoma; SSM=superficial spreading melanoma.

###### Immunohistochemically detected 4E and p4E expression[a](#t2A-fn2){ref-type="fn"}

                                  **No. of**   **4E cyto HS**   **4E cyto HS**   **4E nuc HS**   **4E nuc HS**   **p4E cyto HS**   **p4E cyto HS**   **p4E nuc HS**   **p4E nuc HS**
  ------------------------------- ------------ ---------------- ---------------- --------------- --------------- ----------------- ----------------- ---------------- ----------------
  Nevi                            35           35               1.07±0.12        35              0.25±0.03       34                0.41±0.06         34               0.04±0.02
   Dermal nevi                    21           21               0.93±0.13        21              0.26±0.03       21                0.28±0.06         21               0.04±0.02
   Compound nevi                  11           11               1.14±0.21        11              0.27±0.06       10                0.50±0.14         10               0.04±0.04
   Junctional nevi                3            3                2.03±0.34        3               0.22±0.20       3                 1.06±0.16         3                0.03±0.02
  SSM                             34           34               2.18±0.09        34              0.70±0.09       32                1.62±0.13         32               0.34±0.06
  LM                              22           22               1.93±0.14        22              0.60±0.08       19                1.56±0.13         19               0.34±0.08
   Acral lentiginous melanoma     6            6                2.21±0.40        6               0.92±0.19       5                 1.82±0.13         5                0.38±0.09
   Lentigo maligna melanoma       13           13               1.69±0.11        13              0.47±0.08       11                1.51±0.18         11               0.36±0.13
   Mucosal lentiginous melanoma   3            3                2.40±0.30        3               0.34±0.17       3                 1.34±0.47         3                0.24±0.22
  NM                              16           15               2.24±0.14        15              0.72±0.10       16                1.80±0.24         16               0.65±0.13
  MM                              42           40               2.39±0.06        40              0.86±0.07       42                1.86±0.12         42               0.55±0.07
   Dermal metastases              7            6                2.18±0.27        6               1.11±0.14       7                 1.57±0.32         7                0.61±0.16
   Lymph node metastases          28           28               2.46±0.06        28              0.87±0.08       28                1.94±0.14         28               0.51±0.08
   Distant metastases             7            6                2.31±0.18        6               0.56±0.07       7                 1.86±0.34         7                0.68±0.19
   Clark level I and II           23           23               1.98±0.11        23              0.70±0.13       21                1.47±0.15         21               0.19±0.05
   Clark level ⩾III               44           44               2.16±0.09        44              0.71±0.06       42                1.73±0.12         42               0.54±0.07

Abbreviations: 4E=cytoplasmic and nuclear eukaryotic translation initiation factor 4E; eIF4E=eukaryotic translation initiation factor 4E; HS=histoscores; LM=lentiginous melanomas; MM=metastatic melanoma; NM=nodular melanoma; p4E=phosphorylated eukaryotic translation initiation factor 4E; SSM=superficial spreading melanoma.

In benign nevi and malignant melanoma histopathologic subtypes and MM expressed as HS=area stained × intensity of stain.

###### Statistical analyses (ANOVA and nonparametric *P*-values) of differences in immunohistochemically detected 4E and p4E expression[a](#t2B-fn2){ref-type="fn"}

  ***P*****-values**                    **4E cytoplasmic HS**   **4E nuclear HS**   **p4E cytoplasmic HS**   **p4E nuclear HS**
  ------------------------------------- ----------------------- ------------------- ------------------------ --------------------
  **Dermal/compound/junctional nevi**                                                                        
  ANOVA                                 0.0324                  0.9337              0.0012                   0.9907
  Nonparametric                         0.0775                  0.7618              0.0094                   0.5241
  **Nevi *vs* melanomas**                                                                                    
  ANOVA                                 \<0.0001                \<0.0001            \<0.0001                 \<0.0001
  Nonparametric                         \<0.0001                \<0.0001            \<0.0001                 \<0.0001
  **Clark level I, II *vs* ⩾III**                                                                            
  ANOVA                                 0.2418                  0.9298              0.2063                   0.0010
  Nonparametric                         0.1588                  0.3503              0.1676                   0.0006

Abbreviations: ANOVA=analysis of variance; 4E=cytoplasmic and nuclear eukaryotic translation initiation factor 4E; eIF4E=eukaryotic translation initiation factor 4E; HS=histoscores; p4E=phosphorylated eukaryotic translation initiation factor 4E.

In benign nevi and malignant melanoma histopathologic subtypes and metastatic melanoma expressed as HS=area stained × intensity of stain.

###### Correlation coefficients between patient age, melanocytic lesion histopathologic subtype, Clark level, and immunohistochemically detected 4E and p4E expression[a](#t2C-fn2){ref-type="fn"}

                                      **Age**   **Lesion subtype**   **Clark level**
  ---------------------------------- ---------- -------------------- -----------------
  **Age**                                                            
  Correlation coefficient               ---     0.305                0.838
  *P*-value                             ---     0.0002               0.500
  *N*                                   ---     149                  67
  **Tissue**                                                         
  Correlation coefficient              0.305    ---                  −0.046
  *P*-value                            0.0002   ---                  0.715
  *N*                                   149     ---                  67
  **Clark level**                                                    
  Correlation coefficient              0.838    −0.046               ---
  *P*-value                            0.500    0.715                ---
  *N*                                    67     67                   ---
  **eIF4E cytoplasmic histoscore**                                   
  Correlation coefficient              0.251    0.442                0.126
  *P*-value                            0.002    \<0.0001             0.309
  *N*                                   146     147                  67
  **eIF4E nuclear histoscore**                                       
  Correlation coefficient              0.187    0.319                0.009
  *P*-value                            0.024    \<0.0001             0.939
  *N*                                   146     147                  67
  **p4E cytoplasmic histoscore**                                     
  Correlation coefficient              0.329    0.427                0.147
  P-value                             \<0.0001  \<0.0001             0.252
  *N*                                   143     144                  63
  **p4E nuclear histoscore**                                         
  Correlation coefficient              0.256    0.351                0.397
  *P*-value                            0.002    \<0.0001             0.001
  *N*                                   143     144                  63

Abbreviations: 4E=cytoplasmic and nuclear eukaryotic translation initiation factor 4E; eIF4E=eukaryotic translation initiation factor 4E; HS=histoscores; p4E=phosphorylated eukaryotic translation initiation factor 4E. For purposes of analysis each histopathologic subtype (see [Table 1](#tbl1){ref-type="table"}) was given a numerical code.

HS=area stained × intensity of stain.

###### Determination of the HRs for death from melanoma[a](#t3-fn2){ref-type="fn"} using the Cox proportional hazards model: (A) patient outcome and (B) *P*-values and HRs

  **(A) Patient outcomes**                
  ------------------------------ ---- --- ----
  Nodular melanoma               12   2   14
  Acral lentiginous melanoma     2    4   6
  Lentigo maligna melanoma       3    8   11
  Mucosal lentiginous melanoma   2    1   3
  Metastatic melanoma            14   6   20

  **(B)** ***P*****-values and HRs**                                                                                                 
  ------------------------------------ -------- ------ -------- ------ -------- ------ ---------------- ------ --------------------- ------
  Age                                  0.5222   0.99   0.0044   1.07   0.0319   1.03   0.0785           1.02                          
  eIF4E cytoplasmic histoscore         0.0616   2.22   0.4936   1.45   0.0342   2.01   0.0257           2.09   0.0323                2.03
  eIF4E nuclear histoscore             0.8542   0.92   0.6083   1.36   0.6714   1.16   0.9856           1.01   0.836                 0.93
  p4E cytoplasmic histoscore           0.0052   3.66   0.8992   1.13   0.0031   2.78   0.0217           2.24   0.0555                2.01
  p4E nuclear histoscore               0.0134   2.93   0.2533   2.00   0.0049   2.56   0.0132           2.31   0.0307                2.11
  Adjusted                             Age             Age             Age             Lesion subtype          Age, lesion subtype    

Abbreviations: eIF4E=Eukaryotic translation initiation factor 4E; p4E=phosphorylated eukaryotic translation initiation factor 4E; HR=hazard ratio.

Adjusted for age and lesion histopathologic subtype.

[^1]: Current address: Biothera Pharmaceutical Inc., Eagan, MN, USA.
